Files and links (2)
Published (Version of record)CC BY-NC-ND V4.0, Open Access
Journal article
Keratoacanthoma-appearing melanoma metastases in a patient receiving pembrolizumab therapy
JAAD Case Reports, Vol.2(3), pp.247-249
06/27/2016
DOI: 10.1016/j.jdcr.2016.04.007
PMCID: PMC4927649
PMID: 27408934
Abstract
Introduction:
Pembrolizumab is a new monoclonal antibody chemotherapeutic agent that binds to the programmed cell death–1 receptor and decreases the down-regulation of lymphocytes in patients treated for metastatic melanoma.1 Because this drug is relatively new, little is known about its effect on cutaneous melanoma metastases. We report a case detailing the unexpected keratoacanthomalike appearance of melanoma metastases in a patient receiving pembrolizumab.
Details
- Title: Subtitle
- Keratoacanthoma-appearing melanoma metastases in a patient receiving pembrolizumab therapy
- Creators
- Heather Schopper - University of IowaNicholas M Bontumasi - University of IowaMohammed Milhem - University of IowaKarolyn A Wanat - University of Iowa
- Resource Type
- Journal article
- Publication Details
- JAAD Case Reports, Vol.2(3), pp.247-249
- DOI
- 10.1016/j.jdcr.2016.04.007
- PMID
- 27408934
- PMCID
- PMC4927649
- ISSN
- 2352-5126
- Copyright
- © 2016 by the American Academy of Dermatology, Inc.
- Language
- English
- Date published
- 06/27/2016
- Academic Unit
- Internal Medicine; Dermatology; Orthopedics and Rehabilitation
- Record Identifier
- 9983557355802771
Metrics
95 File views/ downloads
40 Record Views